Newer Modes of Treating Interstitial Lung Disease

Page 1 of 3

Multispecialty Medscape Specialty Sites Allergy & Immunology Anesthesiology Business of Medicine Cardiology Critical Care Dermatology Diabetes & Endocrinology Emergency Medicine Family Medicine Gastroenterology General Surgery Hematology-Oncology HIV/AIDS Infectious Diseases Internal Medicine Multispecialty Nephrology Neurology Ob/Gyn & Women's Health Oncology Ophthalmology Orthopedics Pathology & Lab Medicine Pediatrics Plastic Surgery Psychiatry Public Health Pulmonary Medicine Radiology Rheumatology Transplantation Urology Dental and Oral Health Medical Students Nurses Pharmacists

Search News Search News No instant look-up matches. Search within full reference content by clicking the "SEARCH" button or pressing enter.
Today News Reference Education Log In Register Adverse Drug Events Clinical Trials Dentistry & Oral Health EHR Ethics Health Diversity Healthcare Reform & the ACA Malpractice More

Health IT Czar on Making Meaningful Use 'Meaningful'

CT Screening in Lung Cancer: Risk and Benefit Analysis

CPAP and Walking Capacity in COPD Patients With OSA

E-Cigs: Is It Safe to Vape?

Current Opinion in Pulmonary Medicine

Newer Modes of Treating Interstitial Lung Disease

Wim A. Wuyts, Michiel Thomeer, Maurits G. Demedts Curr Opin Pulm Med. 2011;17(5):332336

Disclosures

Abstract and Introduction Treatment Practical Approach Challenges for the Future Conclusion

Abstract and Introduction

Abstract
Purpose of Review This review critically discusses recent advances in the treatment of idiopathic pulmonary fibrosis (IPF). Moreover, it also focuses

http://www.medscape.com/viewarticle/748591

13/Sep/2013

Newer Modes of Treating Interstitial Lung Disease

Page 2 of 3

References Sidebar

on the practical approach of a patient diagnosed with IPF and uncovers challenges for the future. Recent Findings Treatment can be divided into three major parts. Firstly, many new agents have been tested, but only the combination of Nacetylcysteine with corticosteroids, azathioprine and pirfenidone was able to show some significant effects. In the mean time, many second-generation agents are under development. Lung transplantation has made some major progress by introducing an appropriate allocation system. Finally, as part of best supportive care, several studies show that pulmonary rehabilitation might induce some important effects on quality of life. Summary So, it is clear that major progress has been made in the treatment of IPF, but we are convinced that an orchestrated effort will lead to a better understanding and treatment of this devastating condition. MOST POPULAR ARTICLES
According to PHYSICIANS

RELATED LINKS

1. Statins Linked to Reduced Dementia 2. Chiropractic and Stroke 3. Public in a Haze About Marijuana's Safety 4. Malpractice: Should You Say 'I'm Sorry'? 5. Autoimmunity a Player in Autism
View More

Management of Interstitial Lung Disease in Elderly Patients Pneumonitis and Pulmonary Fibrosis in a Patient Receiving Adjuvant Docetaxel and Cyclophosphamide for Stage 3 Breast Cancer The Current Position of Surgical Lung Biopsy in the Diagnosis of Idiopathic Pulmonary Fibrosis

Introduction
Pulmonary fibrosis is the end stage of many different interstitial lung diseases, including interstitial lung diseases of known cause and idiopathic interstitial pneumonias (Table 1). As interstitial lung diseases cover more than 200 different disease entities, we will focus on the archetype of the fibrotic diseases: idiopathic pulmonary fibrosis (IPF). IPF has an estimated incidence of nine per 100 000 person-years and would affect about 500 000 patients in the USA and Europe.[1] For a long time, the pathogenesis of IPF has been considered as chronic inflammation leading to irreversible formation of fibrosis. In the last American Thoracic Society/European Respiratory Society guidelines, IPF is defined as a specific form of chronic fibrosing interstitial pneumonia limited to the lungs in association with a usual interstitial pneumonia pattern on histology. [2] It is a relentlessly fibrotic disease, consisting of a deposition of extracellular matrix causing architectural distortion of the lungs. IPF is refractory to current pharmacological intervention and mean survival is about 3 years after diagnosis. The present review provides a comprehensive overview of recent developments in the treatment of IPF. Many new antifibrotics of the first generation have been tested with mixed results, but second-generation, more powerful agents are in development. Next to drugs, we will also discuss progress in lung transplantation (LTX) and best supportive care. Moreover, we will provide a practical approach for the physician in selecting appropriate treatment for the individual patient. In the final section, we will focus on the future of treating pulmonary fibrosis on the basis of recently published articles.

Section 1 of 5

Comment

LATEST IN PULMONARY MEDICINE

FDA Panel Backs New COPD Combination Medication Experimental Asthma Drug Fails in Mid-Stage Study Asthma More Common, Severe Among Obese Kids: Study CHMP Backs Dual-Action Bronchodilators for COPD Experimental Asthma Drug Meets Main Goal in Mid-Stage Study
Curr Opin Pulm Med.2011;17(5):332 3362011LippincottWilliams& Wilkins

About Medscape Privacy Policy Terms of Use WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Help

http://www.medscape.com/viewarticle/748591

13/Sep/2013

Newer Modes of Treating Interstitial Lung Disease

Page 3 of 3

All material on this website is protected by copyright, Copyright 1994-2013 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

Top Medical News from Across Medscape You can now readily access the most important news of the day across medicine. Simply click the Today link in the top left of your Medscape homepage. Also on Medscape - Don't miss

Influenza: Vaccinate Kids as Soon as Possible, AAP Says

http://www.medscape.com/viewarticle/748591

13/Sep/2013